Table 1.

Results of complement analyses after eculizumab (1 × 600 mg)a

DayAPH50 (%)C3 (mg/ml)C3d (mU/L)SC5b-9 (ng/ml)
1<50.7048634
3nt0.8337728
7491.1919575
10nt1.0058392
131341.4756360
17nt1.0949369
211140.9149309
24nt0.7656256
  • a nt, not tested.